NEW YORK (Thomson Financial) - Vertex Pharmaceuticals Inc. Monday said an
interim analysis of an ongoing Phase 2b study evaluating telaprevir-based
treatment in patients with genotype 1 chronic hepatitis C virus (HCV) infection
showed 52% of the patients maintained undetectable HCV RNA 12 weeks after
treatment.
All patients in the trial had previously been unable to achieve sustained
virologic response with at least one prior pegylated interferon and ribavirin
regimen.
The company is developing telaprevir for the treatment of HCV in
collaboration with Tibotec. Based on these data, Vertex and Tibotec are planning
to initiate a Phase 3 clinical trial in patients who have failed treatment with
prior pegylated interferon and ribavirin.
Vertex shares closed at $32.24 on Friday.
Christie Rizk
cr/tk1
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|